** Shares of California-based drugmaker Arcutis Biotherapeutics ARQT.O rise 8.2% to $13.20

** Company posted Q4 revenue of $71.36 million late on Tuesday on strong sales of skin disease drug Zoryve, beating analysts' estimate of $60.16 million, according to data compiled by LSEG

** Co also posted quarterly loss of 9 cents per share, narrower than analysts' estimate of 26 cents per share

** Separately, co says the FDA has accepted its marketing application to review Zoryve cream 0.05% to treat mild to moderate atopic dermatitis (AD) in children two to five years old

** Expects to receive regulatory decision by October 12, 2025

** AD, or eczema, is a chronic disease that causes inflammation, redness and irritation of skin

** Zoryve is already approved in the U.S. to treat skin conditions seborrheic dermatitis and plaque psoriasis

** ARQT has risen ~26% in the last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))